Oncolytics Biotech® Inc. Meets Primary Overall Statistical Endpoint in U.S. Phase 2 Study of REOLYSIN® in Squamous Cell Lung

Oncolytics Biotech® Inc. Meets Primary Overall Statistical Endpoint in U.S. 
Phase 2 Study of REOLYSIN® in Squamous Cell Lung Cancer 
CALGARY, March 28, 2013 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics" or the 
"Company") (TSX:ONC) (NASDAQ:ONCY) today announced that it has met the primary 
overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in 
patients with squamous cell carcinoma of the lung (SCCLC) using intravenous 
administration of REOLYSIN in combination with carboplatin and paclitaxel in 
patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are 
chemotherapy naïve for their metastatic or recurrent cancer (REO 021). 
The study is a two-stage design with a primary overall endpoint of objective 
tumor response rate. The Company saw a sufficient number of responses in the 
first stage of the study to proceed with enrollment in the second stage. A 
total of up to 36 patients were to be studied in the second stage. The primary 
endpoint was met if nine or more patients in both stages combined had a 
partial response (PR) or better,which yields a true response rate of 35% or 
more. This endpoint was met after 21 evaluable patients were treated on study, 
nine of which exhibited PRs, while a further nine showed stable disease (SD) 
and three, progressive disease (PD), for a response rate of 42.8% and a 
disease control rate (complete response (CR) + PR + SD) of 85.7%. 
"We are pleased to have met the response rate endpoint, which builds on the 
data we announced from the first stage of this study," said Dr. Brad Thompson, 
President and CEO of Oncolytics. "Based on the positive data seen to date, we 
intend to conduct further studies in this indication." 
The secondary objectives of the trial, for which data has yet to be released, 
are to assess progression-free survival and overall survival for the treatment 
regimen in the study population; to determine the proportion of patients 
receiving the above treatment who are alive and free of disease progression at 
six months; and to assess the safety and tolerability of the treatment regimen 
in the study population. 
About SCC Lung Cancer
The American Cancer Societyestimates that in 2013, approximately 228,190 new 
cases of lung cancer will be diagnosed. Between 85% and 90% of all lung 
cancers are classified as non-small cell lung cancer (NSCLC); squamous cell 
carcinomas (SCC) account for 25-30% of all lung cancers. Lung cancer is by far 
the leading cause of cancer death among both men and women. There will be an 
estimated 159,480 deaths from lung cancer inthe United Statesin 2013, 
accounting for around 27% of all cancer deaths. Lung cancer is the leading 
cause of cancer death, with more people dying each year of lung cancer than 
from colon, breast, and prostate cancers combined. For more information about 
SCC lung cancer, please go towww.cancer.org. 
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development 
of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical 
program includes a variety of human trials including a Phase III trial in head 
and neck cancers using REOLYSIN(®), its proprietary formulation of the human 
reovirus. For further information about Oncolytics, please visit: 
This press release contains forward-looking statements, within the meaning of 
Section27A of the Securities Act of 1933, as amended, and Section 21E of the 
Securities Exchange Act of 1934, as amended. Forward-looking statements, 
including the Company's expectations related to the U.S. Phase II squamous 
cell carcinoma lung cancer trial, future trials in this indication, and the 
Company's belief as to the potential of REOLYSIN as a cancer therapeutic, 
involve known and unknown risks and uncertainties, which could cause the 
Company's actual results to differ materially from those in the 
forward-looking statements. Such risks and uncertainties include, among 
others, the availability of funds and resources to pursue research and 
development projects, the efficacy of REOLYSIN as a cancer treatment, the 
tolerability of REOLYSIN outside a controlled test, the success and timely 
completion of clinical studies and trials, the Company's ability to 
successfully commercialize REOLYSIN, uncertainties related to the research, 
development and manufacturing of pharmaceuticals, changes in technology, 
general changes to the economic environment and uncertainties related to the 
regulatory process. Investors should consult the Company's quarterly and 
annual filings with the Canadian and U.S. securities commissions for 
additional information on risks and uncertainties relating to the 
forward-looking statements. Investors should consider statements that include 
the words "believes", "expects", "anticipates", "intends", "estimates", 
"plans", "projects", "should", or other expressions that are predictions of or 
indicate future events or trends, to be uncertain and forward-looking. 
Investors are cautioned against placing undue reliance on forward-looking 
statements. The Company does not undertake to update these forward-looking 
statements, except as required by applicable laws. 
The Equicom Group Nick Hurst 300 5th Ave. SW, 10th Floor Calgary, Alberta 
T2P 3C4 Tel: 403.218.2835 Fax: 403.218.2830 nhurst@equicomgroup.com  
Dian Griesel, Inc. Susan Forman 396 West Broadway, 2nd Floor New York, NY 
10012 Tel: 212.825.3210 Fax: 212.825.3229 sforman@dgicomm.com   
SOURCE: Oncolytics Biotech Inc. 
To view this news release in HTML formatting, please use the following URL: 
CO: Oncolytics Biotech Inc.
ST: Alberta
-0- Mar/28/2013 10:30 GMT
Press spacebar to pause and continue. Press esc to stop.